Sotera Health (NASDAQ:SHC) Price Target Cut to $17.00 by Analysts at Barclays

Sotera Health (NASDAQ:SHC - Get Free Report) had its price target lowered by stock analysts at Barclays from $18.00 to $17.00 in a report released on Tuesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 25.74% from the company's previous close.

Several other research analysts have also recently commented on SHC. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. The Goldman Sachs Group started coverage on Sotera Health in a research note on Friday, December 6th. They set a "neutral" rating and a $14.00 price objective for the company. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.08.

Sotera Health Stock Performance

SHC stock remained flat at $13.52 during midday trading on Tuesday. The company had a trading volume of 864,109 shares, compared to its average volume of 796,593. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of 54.08 and a beta of 1.91. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The stock's 50 day simple moving average is $13.45 and its 200-day simple moving average is $14.56. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91.

Institutional Trading of Sotera Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Sotera Health by 19.4% in the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company's stock valued at $46,026,000 after buying an additional 447,186 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Sotera Health in the third quarter valued at $1,670,000. Cerity Partners LLC acquired a new stake in shares of Sotera Health in the third quarter valued at $1,489,000. Neo Ivy Capital Management acquired a new stake in shares of Sotera Health in the third quarter valued at $720,000. Finally, Barclays PLC increased its stake in shares of Sotera Health by 169.8% in the third quarter. Barclays PLC now owns 473,597 shares of the company's stock valued at $7,909,000 after buying an additional 298,085 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.